

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MESSINA RICHARD</u>  (Last) (First) (Middle) C/O JUNIPER PHARMACEUTICALS INC. 33 ARCH STREET SUITE 3110  (Street) BOSTON MA 02110  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/19/2018	3. Issuer Name and Ticker or Trading Symbol <u>JUNIPER PHARMACEUTICALS INC [ JNP ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	8,032	D	
Common Stock	250	I	See Footnote <sup>(1)</sup>
Common Stock	250	I	See Footnote <sup>(2)</sup>
Common Stock	250	I	See Footnote <sup>(3)</sup>
Common Stock	8,000	I	See Footnote <sup>(4)</sup>
Common Stock	9,700	I	See Footnote <sup>(5)</sup>
Common Stock	41,000	I	See Footnote <sup>(6)</sup>
Common Stock	14,500	I	See Footnote <sup>(7)</sup>
Common Stock	2,001	I	See Footnote <sup>(8)</sup>
Common Stock	28,000	I	See Footnote <sup>(9)</sup>
Common Stock	6,250	I	See Footnote <sup>(10)</sup>
Common Stock	875	I	See Footnote <sup>(11)</sup>
Common Stock	100,000	I	See Footnote <sup>(12)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

**Explanation of Responses:**

1. shares held by Richard Messina CF Jacqueline Messina UTMA
2. shares held by Richard Messina CF Carolyn Messina UTMA
3. shares held by Richard Messina CF Madeline Messina UTMA
4. Shares held by Equity TR Co TTEE FBO Pamela Brocious SEP
5. Shares held by Steve A. Sanders and Partners
6. Shares held by Citistaffing LLC Profit Sharing
7. Shares held by Summit Capital Associates.
8. Shares held by Benchmark Pellinore Group
9. Shares held by SCA Retirement Plan DTD 1/1/91
10. Shares held by Pamela Brocious M/P PEN PL

11. Shares held by SCA Money Purchase Plan DTD 1/1/94 Attn Richard Messina

12. Shares held by The Benchmark Company LLC - Investment Purposes

**Remarks:**

/s/ Jeffrey Young, Attorney-in-Fact 03/22/2018

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

Power of Attorney

Know all by these presents that the undersigned hereby constitutes and appoints Alicia Secor and Jeffrey Young, and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of Juniper Pharmaceuticals, Inc., a Delaware corporation (the Company), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of March, 2018.

/s/ Richard Messina

\_\_\_\_\_  
Name: RICHARD MESSINA